Egalet Corp (EGLT)

4.73
0.09 1.90
NASDAQ : Health Care
Prev Close 4.82
Open 4.82
Day Low/High 4.63 / 4.83
52 Wk Low/High 4.34 / 16.59
Volume 92.61K
Avg Volume 907.20K
Exchange NASDAQ
Shares Outstanding 25.19M
Market Cap 125.19M
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

EGLT LOSS NOTICE: Rosen Law Firm Reminds Egalet Corporation Investors Of Important Deadline In Class Action - EGLT

EGLT LOSS NOTICE: Rosen Law Firm Reminds Egalet Corporation Investors Of Important Deadline In Class Action - EGLT

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Egalet Corporation securities (NASDAQ:EGLT) from December 15, 2015 through January 9, 2017, inclusive (the "Class Period") of the important March 28,...

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Egalet Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Egalet Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania on behalf...

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Egalet Corporation And Encourages Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Egalet Corporation And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Egalet Corporation ("Egalet" or the "Company") (Nasdaq: EGLT).

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Egalet Corporation - EGLT

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Egalet Corporation - EGLT

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Egalet Corporation securities (NASDAQ: EGLT) from December 15, 2015 through January 9, 2017,...

First Week of March 17th Options Trading For Egalet (EGLT)

First Week of March 17th Options Trading For Egalet (EGLT)

Investors in Egalet Corp saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EGLT options chain for the new March 17th contracts and identified one put and one call contract of particular interest.

Egalet Closes Second Tranche Of $80 Million Secured Debt Financing

Egalet Closes Second Tranche Of $80 Million Secured Debt Financing

--Company also issues options to new salesforce employees--

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of Egalet Corporation

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of Egalet Corporation

Levi & Korsinsky announces it has commenced an investigation of Egalet Corporation (NASDAQ:EGLT) ("Egalet") concerning possible violations of federal securities laws by the Company and/or certain of its officers and...

A Biotech Trio to Like Going Into 2017

A Biotech Trio to Like Going Into 2017

Egalet, Portola Pharmaceuticals and Amicus Therapeutics hold promise for improvement.

Egalet Announces Issuance Of New Patent For Egalet-002 And Guardian™ Technology

Egalet Announces Issuance Of New Patent For Egalet-002 And Guardian™ Technology

--Patent offers protection through February 2030--

Egalet Announces Filing Of Supplemental New Drug Application For OXAYDO® To FDA

Egalet Announces Filing Of Supplemental New Drug Application For OXAYDO® To FDA

--Company seeks to strengthen label with abuse-deterrent data that shows OXAYDO resists syringeability--

Biotech Hits an Inflection Point

Biotech Hits an Inflection Point

The worst appears to be over for this sector; we could see big growth ahead.

Oversold Conditions For Egalet (EGLT)

Oversold Conditions For Egalet (EGLT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Egalet Notified that FDA Will Not Meet PDUFA Goal Date for ARYMO ER

Egalet Notified that FDA Will Not Meet PDUFA Goal Date for ARYMO ER

No additional scientific information or data requested by FDA

Bought Aerie Earlier? Congratulations

Bought Aerie Earlier? Congratulations

An update on some recent small biotech recommendations.

Egalet Stock Sees Short Interest Jump 30%

Egalet Stock Sees Short Interest Jump 30%

The most recent short interest data has been released for the 08/31/2016 settlement date, which shows a 837,041 share increase in total short interest for Egalet Corp , to 3,618,284, an increase of 30.10% since 08/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Egalet Announces Category 1 Abuse-Deterrent Data Demonstrating OXAYDO® Resists Syringeability

Egalet Announces Category 1 Abuse-Deterrent Data Demonstrating OXAYDO® Resists Syringeability

--Data presented today at PAINWeek 2016--